How to Get Grant Funding for Clinical Trials — And Why Early Evidence Still Matters

For teams planning a human clinical study, securing grant funding can be one of the most important — and most challenging — steps between a promising idea and real human data.

There is funding available. But navigating it requires strategy.

Where Clinical Trial Funding Comes From

1. Federal Agencies (NIH, BARDA, DoD)

In the U.S., the National Institutes of Health (NIH) is the largest public funder of biomedical research in the world, supporting everything from early discovery to clinical trials (NIH, 2024). For startups and small businesses, SBIR and STTR programs provide non-dilutive funding specifically designed to support early-stage R&D, including clinical research.

However, NIH grant success rates are often in the 15–25% range depending on the institute and mechanism (NIH Data Book, 2023), making competition significant.

2. Disease Foundations & Philanthropic Organizations

Many disease-focused foundations fund early-phase clinical work, especially when commercial funding is not yet viable. Organizations like the Alzheimer’s Drug Discovery Foundation have historically funded early translational and clinical-stage projects that might otherwise struggle to raise capital (ADDF, 2024).

These grants can be mission-aligned and flexible — but often highly targeted to specific indications.

3. State, International & Specialty Calls

State-level innovation grants, European Horizon programs, and specialized translational research funds also support clinical research. However, eligibility constraints and administrative requirements can be substantial.

Why Grant Funding Is Hard — Especially for Early Clinical Studies

Even though funding exists, early-stage teams frequently face structural friction:

• High competition rates
• Extensive proposal requirements
• Long review timelines
• Funding mechanisms built for later-stage validation

Meta-research has also shown that inefficiencies in biomedical funding and study prioritization are widespread. Some analyses estimate that up to 85% of biomedical research investment may be avoidably wasted due to poor prioritization, design flaws, or failure to address meaningful uncertainties (Chalmers & Glasziou, 2009; Meza, 2025).

For founders trying to run a first human pilot, this creates a painful paradox:

“We need more preliminary data before we can justify funding.”
But generating that preliminary data requires funding.

Why Early Evidence Strengthens Grant Applications

Ironically, the most competitive grant applications often include:

• Pilot human data
• Feasibility results
• Clear endpoint validation
• Preliminary safety signals

Early evidence reduces reviewer uncertainty. It transforms a theoretical proposal into a demonstrated pathway.

But traditional clinical trial infrastructure is expensive. Centralized, site-based models can require significant capital and operational overhead before a study even begins.

That’s where many promising interventions stall.

As Oxperial BioHealth co-founder Daniel Chen shared after completing their first structured human study through Alethios:

“Human data changes how investors and grant reviewers evaluate health innovation. It shifts the narrative from ‘another product’ to ‘validated technology.’ That fundamentally changes the conversation.”

For Oxperial, generating early evidence wasn’t just a scientific milestone — it became part of their funding strategy.

A Complementary Path: Lower the Cost of Early Evidence

At Alethios, we believe early evidence should be infrastructure — not a privilege.

Grant funding remains critical for many programs. But waiting on funding cycles shouldn’t be the only path to generating human data.

That’s why we launched the Alethios Early-Stage Program.

The program is designed for early-stage startups, academic groups, and research teams ready to run real human studies — including pilots, feasibility trials, observational studies, and early RCTs.

It provides:

• Reduced-cost access to decentralized research infrastructure
• Free access to the Study Planner environment
• Recruitment support
• Protocol and IRB templates
• Operational tools for scheduling, adherence tracking, and data capture

This is one of our solutions to break the funding paradox — enabling teams to generate credible early human evidence before or alongside grant applications.

As Daniel Chen put it:

“Start early. You don’t need a pharma-scale trial to begin generating human evidence. Well-designed, focused studies can already create scientific credibility and strategic clarity.”

For teams planning a human clinical study, securing grant funding can be one of the most important — and most challenging — steps between a promising idea and real human data.

Learn more on our Early-Stage Program landing page.

References

National Institutes of Health (NIH). Grants & Funding Overview. 2024.
NIH Data Book. Success Rates for NIH Research Project Grants. 2023.
Alzheimer’s Drug Discovery Foundation (ADDF). Funding Programs Overview. 2024.
Chalmers, I., & Glasziou, P. (2009). Avoidable waste in the production and reporting of research evidence. The Lancet.
Meza, R. (2025). Estimates on biomedical research waste and prioritization inefficiencies.

‍